ICU新冠患者合并侵袭性肺曲霉病的危险因素:法国多中心回顾性队列
该法国多中心回顾性队列纳入366例ICU新冠患者,其中21例(5.7%)诊断为可能侵袭性肺曲霉病(IPA),在因病情恶化行呼吸道采样的108例中占19.4%。阿奇霉素治疗≥3天与IPA诊断相关(OR 3.1,95%CI 1.1-8.5,p=0.02),IPA患者总死亡率更高(71.4% vs 36.8%,p<0.01)。
要点
- ICU新冠患者中可能IPA发生率为5.7%,病情恶化采样者中达19.4%
- 阿奇霉素治疗≥3天与IPA诊断独立相关(OR 3.1)
- 合并IPA者总死亡率显著升高(71.4% vs 36.8%)
核心结论
- IPA是重症新冠患者相对常见的并发症,并导致死亡率增加。
- 阿奇霉素具有免疫调节特性,可能增加新冠患者对IPA的易感性。
研究设计与样本
- 法国四家ICU的回顾性队列研究,纳入所有连续住院的新冠患者中病情继发恶化且至少送检一次呼吸道样本至真菌实验室者。
- 采用强化的IPA检测策略,包括七项真菌学标准。
- 免疫功能低下者按EORTC/MSGERC分类诊断为可能IPA,其余按近期新冠相关IPA分类诊断。
主要发现
- 366例ICU新冠患者中21例(5.7%)诊断为可能IPA;在108例因病情恶化行呼吸道采样的患者中占19.4%。
- IPA与非IPA患者在年龄、性别、病史及入院和住院期间严重程度方面无显著差异。
- 阿奇霉素治疗≥3天与可能IPA诊断相关(OR 3.1,95%CI 1.1-8.5,p=0.02)。
- 大剂量地塞米松与IPA发生呈趋势性关联。
- IPA患者总死亡率高于非IPA患者(15/21,71.4% vs 32/87,36.8%,p<0.01)。
临床怎么用
- 对ICU新冠患者病情恶化时应考虑IPA可能,并送检呼吸道样本行真菌学检查。
- 关注阿奇霉素使用≥3天患者,警惕其IPA风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The main objective of this study was to determine the incidence of invasive pulmonary aspergillosis (IPA) in patients with coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU), and to describe the patient characteristics associated with IPA occurrence and to evaluate its impact on prognosis. METHODS: We conducted a retrospective cohort study including all successive COVID-19 patients, hospitalized in four ICUs, with secondary deterioration and one or more respiratory samples sent to the mycology department. We used a strengthened IPA testing strategy including seven mycological criteria. Patients were classified as probable IPA according to the European Organization for Research and Treatment of Cancer (EORTC)/Mycoses Study Group Education and Research Consortium (MSGERC) classification if immunocompromised, and according to the recent COVID-19-associated IPA classification otherwise. RESULTS: Probable IPA was diagnosed in 21 out of the 366 COVID-19 patients (5.7%) admitted to the ICU and in the 108 patients (19.4%) who underwent respiratory sampling for deterioration. No significant differences were observed between patients with and without IPA regarding age, gender, medical history and severity on admission and during hospitalization. Treatment with azithromycin for ≥3 days was associated with the diagnosis of probable IPA (odds ratio 3.1, 95% confidence interval 1.1-8.5, p = 0.02). A trend was observed with high-dose dexamethasone and the occurrence of IPA. Overall mortality was higher in the IPA patients (15/21, 71.4% versus 32/87, 36.8%, p < 0.01). CONCLUSION: IPA is a relatively frequent complication in severe COVID-19 patients and is responsible for increased mortality. Azithromycin, known to have immunomodulatory properties, may contribute to increase COVID-19 patient's susceptibility to IPA.
引用
- Dellière S, Dudoignon E, Fodil S, et al. Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clin Microbiol Infect. 2020. PMID: 33316401. doi:10.1016/j.cmi.2020.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。